Rinsulin NPH

Rinsulin NPH is an intermediate-acting human insulin biosimilar developed by Geropharm using recombinant DNA technology. It is an isophane insulin suspension that acts as an agonist at the insulin receptor (INSR), facilitating glucose uptake in muscle and adipose tissue while inhibiting hepatic glucose production. The drug has an onset of action of approximately 1.5 hours, a peak effect between 4 and 12 hours, and a duration of action up to 24 hours. It is indicated for the management of Type 1 diabetes mellitus, Type 2 diabetes mellitus, and gestational diabetes. Geropharm utilizes full-cycle production technology to manufacture this biologic, which is positioned as a biosimilar to Humulin NPH.

Brand names

Rinsulin NPH

Other names

isophane insulinhuman insulin isophaneNPH insulin